CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Jerini AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Jerini AG
5 Riverwalk
Citywest Business Campus
Dublin, 24  Ireland Ticker: JI4 JI4
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Jerini AG is a Germany-based company, operating in the pharmaceutical sector. Its focus is on the discovery, development and commercialization of peptide-based services and drugs to treat diseases with limited or no treatment options. The Company’s research and development pipeline includes products from such areas as ophthalmology, oncology, inflammation diseases, hereditary angioedema and others. Its main product, Firazyr, is used for the treatment of hereditary angioedema (HAE). As at December 31, 2008, the Company operated through eight subsidiaries including Jerini US, Inc. in the United States, JPT Peptide Technologies GmbH (JPT) in Germany and Jerini Trading Ltd. on Malta, among others. As of 1/7/2019, the Company is part of Shire PLC, which is owned by Takeda Pharmaceutical Company Limited.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/200912/31/2008Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Supervisory Board AndreasDe Maiziere 10/1/2009 3/12/2009
Member of the Executive Board, Chief Executive Officer JonathanScott 1/1/2009 1/1/2009
Member of the Executive Board, Chief Financial Officer ChristianVon Volkmann 10/10/2008 10/10/2008
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Jerini AG
Jerini Trading Ltd.
Jerini US, Inc.
JI4
JPT Peptide Technologies GmbH

General Information
Number of Employees: 65 (As of 9/30/2009)
Outstanding Shares: 58,942,179 (As of 9/30/2009)
Stock Exchange: ETR


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023